Publications
Articles:
Scheff, Ronald J. Breast cancer and the new taxanes: focus on nab-paclitaxel. Community Oncology 5(7), Supplement 8, 2008: pp 7-13.
Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D, Zaroulis C. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Critical Rev Hematol/Oncol 39:31-42, 2001.
Huang Y, Hayes RL, Wertheim S, Arbit E, Scheff R. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report. Critical Rev Hematol/Oncol 57:17-23, 2001.
Editorial:
Scheff R. Fulvestrant offers an attractive treatment option for postmenopausal breast cancer.
Community Oncology 4(4):231-2, 2007.
Abstracts:
V. S. Blinder, M. Mahadeo, L. T. Vahdat, H. T. Gold, I. De Melo-Martin, M. K. Hayes, R. J. Scheff, A. Moore, E. Chuang and M. Mazumdar. Ethnicity and return to work in breast cancer survivors: An exploratory qualitative study. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 26, No 15S (May 20 Supplement), 2008: 20532.
Scheff R, Maslak P, Jakubowski A. Approaches in the treatment of relapsed (rel) versus refractory (ref) acute myelogenous leukemia (AML). Proceedings of ASCO, 1995.
Huang Y, Hayes RL, Wertheim S, Scheff R, Arbit E. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy. American College of Physicians
National Competition, October 1999, Amer Soc of Internal Med, 2000.
Huang Y, Hayes RL, Wertheim S, Scheff R, Arbit E. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy. American College of Physicians
Local Competition, November 1999. Selected for poster presentation at the Associates Meeting Downstate Competition, New York, NY, April, 2000 [First place winner Research
category].
Huang Y, Hayes RL, Wertheim S, Arbit E, Scheff R. Treatment of refractory malignant glioma with adoptive immunotherapy: a case report. Poster presentation at the International
Conference on Advances in Cancer Immunotherapy, Cell-based Therapies session, Princeton, NJ, March 2000.
Hayes RL, Lazaro L, Odaimi M, Scheff R, Burton J. Immunologic monitoring of peripheral blood changes in patients with stage IV malignant melanoma or renal cell cancer treated with
sequential recombinant human GM-CSF (Leukine), interleukin-2 (IL-2, Proleukin) and PEG-interferon a2b (PEG-IFN, PEG-Intron) on a phase I/II clinical trial. Proceedings of Amer
Assoc Canc Res, 2003.
Hayes RL, Serventi J, Odaimi M, Scheff R, Zaroulis CG, Silverman P, Grosman I, Lederman G, Pannullo S. Synergistic efficacy of sequential fractionated stereotactic radiosurgery plus paclitaxel (FSRS T) and adoptive cellular immune therapy (ITX) using interleukin-2 and activated killer cells (LAK). Proceedings of Amer Assoc Canc Res, 2003.
Burton JD, El-Sayah D, Dib E, Badine E, Forte F, Terjanian T, Odaimi M, Vesoniaraki M, Lowry J, Scheff R. Phase I/II trial of standard-dose carboplatinum/gemcitabine escalating doses of celexicob for 1st-line treatment of stage IIIB/IV NSCLC. Proceedings of ASCO, 2003.
Letter:
Scheff RJ, Rolla AR. The eosinophilia-myalgia syndrome [letter]. Ann Intern Med 112(12): 964-5, 1990.
